Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

Rhea-AI Summary

Ovid Therapeutics (NASDAQ: OVID) will host an investor and media event on June 12, 2025, focusing on biomarkers in epilepsy and their OV329 clinical development program. The event will feature Dr. Alexander Rotenberg, a leading pediatric neurologist from Boston Children's Hospital and Harvard Medical School. The presentation will highlight how advanced imaging and radiological tools are being used to identify biological target engagement in drug development. OV329, Ovid's next-generation GABA-aminotransferase inhibitor, is designed to address treatment-resistant seizures, with topline results expected in Q3 2025. The drug aims to provide optimal GABA levels with better safety and tolerability compared to vigabatrin. Currently, about 40% of epilepsy patients continue experiencing seizures despite available treatments. The event will be held at Ovid's New York headquarters and simultaneously webcast.

Emerging Biomarkers in the Clinical Development of Epilepsy Medicines and OV329 Program Highlights

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on Thursday, June 12, 2025, on the topic of applying Biomarkers in Epilepsy, including their strategic use to demonstrate the pharmacodynamic activity of the Company’s OV329 clinical development program. World-leading expert, Dr. Alexander Rotenberger will join company management to discuss the emerging use of a wide range of biomarkers for the study of anti-seizure medicines. The event will take place at Ovid’s headquarters in New York’s Hudson Yards from 9:30 to 10:30 am ET and will be webcast simultaneously.

Sophisticated imaging and radiological tools are increasingly enabling medicines developers to leverage biomarkers earlier in clinical development to identify signals of biological target engagement and pharmacodynamic activity. Discussion will focus on how these tools drive evidence informed approaches in drug development and provide insight into potential clinical outcomes. Ovid management will describe the exploratory biomarkers in use to measure its next-generation GABA-aminotransferase (GABA-AT) inhibitor program, OV329, which is anticipated to have a topline readout in Q3 2025.

Keynote speaker:

• Leading pediatric neurologist and epileptologist Alexander Rotenberg, M.D., Ph.D. Professor of Neurology at Boston Children’s Hospital and Harvard Medical School, and Director of the Epilepsy Monitoring Unit at Boston Children’s Hospital, and the Experimental Neurophysiology Core at F.M. Kirby Center of Neurobiology
  

Unfortunately, nearly 40 percent of people living with epilepsy continue to experience seizures despite existing medicines. OV329 is a next-generation GABA-AT inhibitor, that was rationally designed to work differently from current medicines and may offer a novel approach for patients with treatment-resistant seizures. OV329 seeks to endogenously deliver optimal levels of GABA to reduce seizures and provide a preferable safety and tolerability profile relative to the first-generation, GABA-AT inhibitor, vigabatrin. OV329 is currently completing a Phase 1 study that is evaluating its effects on multiple pharmacodynamic biomarkers, safety, tolerability, and pharmacokinetics.

Interested in attending or participating remotely:

To register, please visit: Registration Link

A live webcast of the presentation can be accessed through the Events & Presentations section of Ovid's website at https://investors.ovidrx.com.

About Ovid Therapeutics

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. For more information about these and other Ovid research programs, please visit www.ovidrx.com.

Forward-Looking Statements

This press release includes certain disclosures by Ovid that contain “forward-looking statements” including, without limitation: statements regarding the expected timing of initiation, completion, and results and data of Ovid’s clinical studies; the potential use and development of OV329, OV350, OV4071 and other compounds from Ovid’s library of direct activators of KCC2; and other statements that are not historical fact. You can identify forward-looking statements because they contain words such as “anticipates,” “believes,” “expects,” “intends,” “may,” “plan,” “potentially,” and “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid’s ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its business strategy or unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption “Risk Factors” in Ovid’s most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”), and in subsequent and future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

Media and Investor Relations:
Victoria Fort
vfort@ovidrx.com

FAQ

When will Ovid Therapeutics (OVID) release topline results for OV329?

Ovid Therapeutics expects to release topline results for OV329 in Q3 2025.

What is the purpose of Ovid Therapeutics' OV329 drug?

OV329 is a next-generation GABA-AT inhibitor designed to treat treatment-resistant seizures by delivering optimal levels of GABA with better safety and tolerability compared to vigabatrin.

Who is the keynote speaker at Ovid Therapeutics' June 2025 investor event?

Dr. Alexander Rotenberg, Professor of Neurology at Boston Children's Hospital and Harvard Medical School, will be the keynote speaker.

What percentage of epilepsy patients still experience seizures despite existing treatments?

According to the press release, nearly 40 percent of people living with epilepsy continue to experience seizures despite existing medicines.

When and where is Ovid Therapeutics' investor event taking place?

The event will take place on Thursday, June 12, 2025, from 9:30 to 10:30 am ET at Ovid's headquarters in New York's Hudson Yards, with simultaneous webcast availability.